Skip to Content

Cancer Quality Report

When you're diagnosed with cancer, you want a treatment program recognized for its commitment to providing comprehensive and patient-centered care.

The cancer program at North Kansas City Hospital is accredited by the Commission on Cancer, a program of the American College of Surgeons dedicated to improving survival rates and quality of life for people with cancer.

This accreditation ensures our cancer program meets the highest standards of evidence-based practices and provides quality care to you.

Through the Commission on Cancer, we have access to reporting tools called Cancer Program Practice Profile Reports (CP3R) that help with benchmarking and improving our outcomes. 

The comparisons below are from the Commission on Cancer website and reflect the most current data.

Breast Cancer

Reporting Period: 2015

Radiation is administered within one year of diagnosis for women under age 70 receiving breast-conserving surgery.

NKCH 100%
Region 95%
Missouri 96%
National 92%

Combination chemotherapy is considered or administered within four months of diagnosis for women under 70 with AJCC T1c N0 M0 or Stage 2 or 3 estrogen receptor-negative and progesterone-receptor negative breast cancer.

*Only 10 patients in our sample size and one patient (10%0 had delay of chemo due to other health issue.

NKCH 90%
Region 98%
Missouri 95%
National 93%

Tamoxifen or third-generation aromatase inhibitors are considered or administered within one year of diagnosis for women with T1c N0 M0 or Stage 2 or 3 estrogen receptor-positive and/or progesterone-receptor positive breast cancer.

NKCH 98%
Region 97%
Missouri 95%
National 92%

Colon Cancer

Reporting Period: 2015

Post-surgery chemotherapy is considered or administered within four months of diagnosis for people under the age of 80 with Stage 3 lymph node-positive colon cancer.

NKCH 100%
Region 94%
Missouri 92%
National 89%